Brief Review Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants— Griffin 2020

This is a brief audio review. In the article Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants published, 2020 by Griffin and Colleagues, The outcomes and key points are as noted: Nirsevimab resulted in less Respiratory Syncitial Virus associated lower respiratory tract infection and hospitalization in healthy preterm infants, compared to preterm infants. Nirsevimab reduced RSV associated lower respiratory tract infection and hospitalizations when compared to placebo by 70.1%, p<0.001; and by 78.4%, p<0.001. This was a Randomized controlled trial with 1453 patients who were patients who were healthy infants with a history of preterm birth, gestational age of 29 weeks and 0 days to 34 weeks and 6 days, who were less than 1 year old during their first RSV season. Patients who were excluded include those who recieved broadly accepted respiratory syncytial virus therapies or prophylaxis other than nirsevimab.

Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP; Nirsevimab Study Group. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556. Erratum in: N Engl J Med. 2020 Aug 13;383(7):698. PMID: 32726528.